Orient Cement is currently trading at Rs. 428.00, up by 8.55 points or 2.04% from its previous closing of Rs. 419.45 on the BSE.
The scrip opened at Rs. 425.05 and has touched a high and low of Rs. 430.00 and Rs. 422.00 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 438.00 on 01-Dec-2020 and a 52 week low of Rs. 114.50 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 438.00 and Rs. 415.00 respectively. The current market cap of the company is Rs. 10,602.74 crore.
The promoters holding in the company stood at 42.04%, while public held 57.96%.
Granules India’s wholly-owned foreign subsidiary -- Granules Pharmaceuticals Inc, has received approval for its abbreviated new drug application (ANDA) for Penicillamine capsules USP, 250 mg from the US Food and Drug Administration (USFDA). It is bioequivalent to the reference listed drug product (RLD), Cuprimine of Bausch Health Americas, Inc. The product would be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly.
Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients withsevere, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |